Randomized phase II clinical trial to assess MUC1 specific immune response to L-BLP25 vaccine in addition to standard therapy in newly diagnosed high-risk prostate cancer.

Nishith K. Singh, Marijo Bilušić, Joseph W. Kim, Christopher R. Heery, Martin Falk, Bradford J. Wood, Peter A. Pinto, William L. Dahut, Aradhana Kaushal, Anna Couvillon, Myrna Rauckhorst, Peter L. Choyke, Barış Türkbey, Jane B. Trepel, Kwong Y. Tsang, Jeffrey Schlom, James L. Gulley, Ravi A. MadanJournal of Clinical Oncology 2012 · DOI

Abstract

TPS4701 Background: In high-risk prostate cancer, radiation therapy (RT) + androgen deprivation therapy (ADT) improve survival. Nonetheless, 10-year disease specific mortality is about 25%. L-BLP25 is a cancer vaccine containing the BLP25 lipopeptide that targets MUC1 tumor antigen. It may enhance immune targeting of cells that express MUC1 (e.g. prostate cancer). In murine models, RT synergizes with vaccine-induced anti-cancer immunity (augments T-cell mediated cancer cytolysis, up-regulates cellular Fas and co-stimulatory/adhesion molecules). ADT augments T-cell trafficking to prostate. Immune response to combining the three (L-BLP25 + RT + ADT) is not known. The current trial intends to study this immune response to L-BLP25 + RT + ADT and compare it to RT+ADT alone. Using ELISPOT, endo-rectal MRI and serial prostate biopsies, this trial was designed to correlate systemic immune response with changes in tumor imaging and/or tumor microenvironment after treatment with L-BLP25. This trial may provide insight into immune response biomarkers that are most appropriate in this setting. Methods: A randomized (1:1), open-label, phase II trial of 42 pts is planned. Eligibility: Adult males with newly diagnosed high-risk prostate cancer (T3 or Gleason ≥ 8 or seminal vesicle involvement or N1 or PSA>20) and HLA-A2/A3 positivity (to allow for ELISPOT analysis). The vaccine arm will receive RT + 2-year ADT + L-BLP25. Standard arm will receive RT + 2-year ADT. L-BLP25 vaccine schedule: biweekly X 5 starting with neo-adjuvant ADT, then 6 weekly X 4 starting with RT. A single 300mg/m2 cyclophosphamide infusion (decreases suppressor T-cells) will be given 3 days before L-BLP25 to enhance immune response in the vaccine arm. The impact of L-BLP25 + RT+ADT on MUC-1-specific systemic immune response will be determined using interval peripheral blood ELISPOT assays. Endo-rectal coil MRI will be done before and after treatment to study prostate signal changes for correlative and predictive analysis. MRI-UltraSound guided lesion-targeted serial prostate biopsies will be obtained to assess immune response in tumor microenvironment. Two pts have been enrolled.
BibTeX
@article{singh2012randomized,
  author = {Nishith K. Singh and Marijo Bilušić and Joseph W. Kim and Christopher R. Heery and Martin Falk and Bradford J. Wood and Peter A. Pinto and William L. Dahut and Aradhana Kaushal and Anna Couvillon and Myrna Rauckhorst and Peter L. Choyke and Barış Türkbey and Jane B. Trepel and Kwong Y. Tsang and Jeffrey Schlom and James L. Gulley and Ravi A. Madan},
  title = {{Randomized phase II clinical trial to assess MUC1 specific immune response to L-BLP25 vaccine in addition to standard therapy in newly diagnosed high-risk prostate cancer.}},
  journal = {Journal of Clinical Oncology},
  year = {2012},
  doi = {10.1200/jco.2012.30.15\_suppl.tps4701},
}

Loading related content...

Figure